MedTech Dive

Abbott receives FDA warning letter over Freestyle Libre CGMs

Abbott needs to conduct more performance testing to ensure its FreeStyle Libre devices are accurate, FDA inspectors found.
Nasdaq

Abbott Says Data Show FreeStyle Libre 3 System Most Accurate 14-Day Continuous Glucose Monitor

(RTTNews) - Abbott (ABT) said late-breaking clinical data showed the FreeStyle Libre 3 system has an overall mean absolute relative difference (MARD) of 7.9%, making it the first and only 14-day ...
Nasdaq

Abbott's FreeStyle Libre® 3 Receives U.S. FDA Clearance - Features World's Smallest, Thinnest and Most Accurate 14-Day Glucose Sensor

The FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor1, with readings sent directly to a smartphone every minute.2 Designed for access and affordability, the FreeStyle ...
MobiHealthNews

Canada approves Abbott’s FreeStyle Libre 2 for adults and children with diabetes

Abbott’s continuous glucose monitoring system, the FreeStyle Libre 2, has been approved in Canada for adults and children four years and older with diabetes. The FreeStyle Libre 2 system continuously ...
FOX8 Cleveland

Late-Breaking Data Demonstrate Abbott's FreeStyle Libre® 3 System is Most Accurate 14-Day Continuous Glucose Monitor

MARD is considered the simplest measurement of sensor accuracy 2 and represents the difference between a CGM system's glucose readings and a reference blood glucose measurement. The lower the MARD, ...